NovaBay Pharmaceuticals, Inc. (formerly known as NovaCal Pharmaceuticals, Inc.) Receives Allowance of Patent Covering NeutroPhase(TM) Product

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (AMEX & TSX: NBY, http://novabaypharma.com), a biopharmaceutical company developing products for the treatment or prevention of a wide range of multi-drug resistant bacterial and viral infections, including MRSA, has added an important piece to its patent portfolio with the allowance of a US Patent covering the use of NeutroPhaseâ„¢ in wound care applications, under conditions that the company believes are optimal for efficacy and stability. In September 2007, NovaBay received 510(K) approval from the US Food and Drug Administration to market NeutroPhase, also known as NVC-101.

Back to news